NCT07010302 Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Status NOT_YET_RECRUITING Phase PHASE4
NCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05987423 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis Status RECRUITING Phase PHASE3
NCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Status RECRUITING Phase PHASE3
NCT05199688 A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Status RECRUITING Phase PHASE3
NCT04963270 A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Status TERMINATED Phase PHASE3
NCT04660539 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) Status COMPLETED Phase PHASE3
NCT02073279 Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Status COMPLETED Phase PHASE3
NCT02028884 Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) Status COMPLETED Phase PHASE3